NO316425B1 - Orale, farmasöytiske doseringsformer innbefattende en protonpumpeinhibitorog et prokinetisk middel, fremgangsmåte for fremstilling av slikedoseringsformer og anvendelse derav - Google Patents
Orale, farmasöytiske doseringsformer innbefattende en protonpumpeinhibitorog et prokinetisk middel, fremgangsmåte for fremstilling av slikedoseringsformer og anvendelse derav Download PDFInfo
- Publication number
- NO316425B1 NO316425B1 NO19974070A NO974070A NO316425B1 NO 316425 B1 NO316425 B1 NO 316425B1 NO 19974070 A NO19974070 A NO 19974070A NO 974070 A NO974070 A NO 974070A NO 316425 B1 NO316425 B1 NO 316425B1
- Authority
- NO
- Norway
- Prior art keywords
- dosage form
- proton pump
- pump inhibitor
- tablet
- pellets
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title claims description 93
- 229940126409 proton pump inhibitor Drugs 0.000 title claims description 88
- 239000000612 proton pump inhibitor Substances 0.000 title claims description 88
- 239000002325 prokinetic agent Substances 0.000 title claims description 53
- 238000000034 method Methods 0.000 title claims description 25
- 238000002360 preparation method Methods 0.000 title claims description 16
- 230000008569 process Effects 0.000 title claims description 14
- 239000010410 layer Substances 0.000 claims description 121
- 239000011247 coating layer Substances 0.000 claims description 84
- 239000008188 pellet Substances 0.000 claims description 80
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 33
- 239000002253 acid Substances 0.000 claims description 32
- 238000000576 coating method Methods 0.000 claims description 25
- 239000011248 coating agent Substances 0.000 claims description 24
- 239000008187 granular material Substances 0.000 claims description 20
- 238000000926 separation method Methods 0.000 claims description 20
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 18
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 14
- 229960000381 omeprazole Drugs 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 239000007900 aqueous suspension Substances 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 230000002378 acidificating effect Effects 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 159000000011 group IA salts Chemical class 0.000 claims description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 3
- 239000007916 tablet composition Substances 0.000 claims description 3
- 239000007963 capsule composition Substances 0.000 claims description 2
- 229960003174 lansoprazole Drugs 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims 1
- 239000011162 core material Substances 0.000 description 35
- 150000001875 compounds Chemical class 0.000 description 33
- 239000013543 active substance Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 239000000126 substance Substances 0.000 description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000009501 film coating Methods 0.000 description 12
- 239000007888 film coating Substances 0.000 description 12
- KWORUUGOSLYAGD-UHFFFAOYSA-N magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]benzimidazol-1-ide Chemical compound [Mg+2].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C.N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-UHFFFAOYSA-N 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 239000000654 additive Substances 0.000 description 11
- 239000011230 binding agent Substances 0.000 description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 9
- -1 cisapnd Chemical class 0.000 description 9
- 238000009505 enteric coating Methods 0.000 description 9
- 239000002702 enteric coating Substances 0.000 description 9
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 238000009492 tablet coating Methods 0.000 description 9
- 239000002700 tablet coating Substances 0.000 description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 8
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- 239000004014 plasticizer Substances 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 210000004211 gastric acid Anatomy 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 230000000181 anti-adherent effect Effects 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 5
- 150000002431 hydrogen Chemical group 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 238000009475 tablet pressing Methods 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000000395 magnesium oxide Substances 0.000 description 4
- 235000012245 magnesium oxide Nutrition 0.000 description 4
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 229960000620 ranitidine Drugs 0.000 description 4
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- LRZSAGKIMYFLHY-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;dihydrate Chemical compound O.O.OC(=O)CC(O)(C(O)=O)CC(O)=O LRZSAGKIMYFLHY-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 208000000689 peptic esophagitis Diseases 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229950008882 polysorbate Drugs 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010030216 Oesophagitis Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 239000002216 antistatic agent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940054066 benzamide antipsychotics Drugs 0.000 description 2
- 150000003936 benzamides Chemical class 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical class [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 235000012254 magnesium hydroxide Nutrition 0.000 description 2
- 229960000869 magnesium oxide Drugs 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 2
- 229960004503 metoclopramide Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000011824 nuclear material Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000006179 pH buffering agent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- 238000005563 spheronization Methods 0.000 description 2
- 229940071117 starch glycolate Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 description 1
- 108091005482 5-HT4 receptors Proteins 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 241001082241 Lythrum hyssopifolia Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229910020038 Mg6Al2 Inorganic materials 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000000159 acid neutralizing agent Substances 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 229940024548 aluminum oxide Drugs 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229940095643 calcium hydroxide Drugs 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 229940031954 dibutyl sebacate Drugs 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000009063 long-term regulation Effects 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- OUHCLAKJJGMPSW-UHFFFAOYSA-L magnesium;hydrogen carbonate;hydroxide Chemical compound O.[Mg+2].[O-]C([O-])=O OUHCLAKJJGMPSW-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 description 1
- 229960004085 mosapride Drugs 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002071 phenylalkoxy group Chemical group 0.000 description 1
- 150000003022 phthalic acids Chemical class 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000004950 trifluoroalkyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9600072A SE9600072D0 (sv) | 1996-01-08 | 1996-01-08 | New oral formulation of two active ingredients II |
| PCT/SE1996/001736 WO1997025065A1 (en) | 1996-01-08 | 1996-12-20 | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO974070D0 NO974070D0 (no) | 1997-09-04 |
| NO974070L NO974070L (no) | 1997-10-06 |
| NO316425B1 true NO316425B1 (no) | 2004-01-26 |
Family
ID=20400970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19974070A NO316425B1 (no) | 1996-01-08 | 1997-09-04 | Orale, farmasöytiske doseringsformer innbefattende en protonpumpeinhibitorog et prokinetisk middel, fremgangsmåte for fremstilling av slikedoseringsformer og anvendelse derav |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6132771A (is) |
| EP (1) | EP0814840B1 (is) |
| JP (1) | JPH11501949A (is) |
| KR (1) | KR100486057B1 (is) |
| CN (1) | CN1142792C (is) |
| AR (1) | AR008750A1 (is) |
| AT (1) | ATE228010T1 (is) |
| AU (1) | AU712572B2 (is) |
| BR (1) | BR9607344A (is) |
| CA (1) | CA2214033C (is) |
| CZ (1) | CZ280897A3 (is) |
| DE (1) | DE69624910T2 (is) |
| DK (1) | DK0814840T3 (is) |
| EE (1) | EE9700195A (is) |
| ES (1) | ES2185816T3 (is) |
| HU (1) | HUP9904094A3 (is) |
| ID (1) | ID18383A (is) |
| IL (1) | IL121652A (is) |
| IS (1) | IS4550A (is) |
| MX (1) | MX9706769A (is) |
| NO (1) | NO316425B1 (is) |
| NZ (1) | NZ325976A (is) |
| PL (1) | PL322176A1 (is) |
| PT (1) | PT814840E (is) |
| SE (1) | SE9600072D0 (is) |
| SK (1) | SK117097A3 (is) |
| TR (1) | TR199700917T1 (is) |
| WO (1) | WO1997025065A1 (is) |
| ZA (1) | ZA9610938B (is) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| SE9600072D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients II |
| SE510650C2 (sv) * | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
| ES2137862B1 (es) * | 1997-07-31 | 2000-09-16 | Intexim S A | Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion. |
| US6096340A (en) | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| JP4546643B2 (ja) * | 1997-12-08 | 2010-09-15 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 酸不安定な活性化合物を含有する新規の坐剤形 |
| DK173431B1 (da) * | 1998-03-20 | 2000-10-23 | Gea Farmaceutisk Fabrik As | Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs |
| US6328994B1 (en) | 1998-05-18 | 2001-12-11 | Takeda Chemical Industries, Ltd. | Orally disintegrable tablets |
| TWI257311B (en) | 1998-07-28 | 2006-07-01 | Takeda Chemical Industries Ltd | Rapidly disintegrable solid preparation |
| SE9803772D0 (sv) * | 1998-11-05 | 1998-11-05 | Astra Ab | Pharmaceutical formulation |
| WO2000059314A1 (en) * | 1999-04-01 | 2000-10-12 | Wm. Wrigley Jr. Company | Long flavor duration releasing structures for chewing gum |
| US6428809B1 (en) * | 1999-08-18 | 2002-08-06 | Microdose Technologies, Inc. | Metering and packaging of controlled release medication |
| US6521255B2 (en) * | 2000-01-13 | 2003-02-18 | Osmotica Corp. | Osmotic device containing ranitidine and a prokinetic agent |
| US6667042B2 (en) | 2000-02-24 | 2003-12-23 | Advancis Pharmaceutical Corp. | Fluroquinilone antibiotic product, use and formulation thereof |
| US6663891B2 (en) | 2000-02-24 | 2003-12-16 | Advancis Pharmaceutical Corp. | Erythromyacin antibiotic product, use and formulation thereof |
| US6638532B2 (en) | 2000-02-24 | 2003-10-28 | Advancis Pharmaceutical Corp. | Tetracycline—doxycycline antibiotic composition |
| US6669948B2 (en) | 2000-02-24 | 2003-12-30 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
| US6663890B2 (en) | 2000-02-24 | 2003-12-16 | Advancis Pharmaceutical Corp. | Metronidazole antibiotic product, use and formulation thereof |
| US7025989B2 (en) * | 2000-02-24 | 2006-04-11 | Advancis Pharmaceutical Corp. | Multiple-delayed released antibiotic product, use and formulation thereof |
| US6632453B2 (en) | 2000-02-24 | 2003-10-14 | Advancis Pharmaceutical Corp. | Ciprofoxacin-metronidazole antibiotic composition |
| US6627222B2 (en) | 2000-02-24 | 2003-09-30 | Advancis Pharmaceutical Corp. | Amoxicillin-dicloxacillin antibiotic composition |
| US6667057B2 (en) | 2000-02-24 | 2003-12-23 | Advancis Pharmaceutical Corp. | Levofloxacin antibiotic product, use and formulation thereof |
| US6610328B2 (en) | 2000-02-24 | 2003-08-26 | Advancis Pharmaceutical Corp. | Amoxicillin-clarithromycin antibiotic composition |
| US6623758B2 (en) | 2000-02-24 | 2003-09-23 | Advancis Pharmaceutical Corp. | Cephalosporin-metronidazole antibiotic composition |
| WO2001062195A1 (en) | 2000-02-24 | 2001-08-30 | Advancis Pharmaceutical Corporation | Antibiotic and antifungal compositions |
| US6991807B2 (en) * | 2000-02-24 | 2006-01-31 | Advancis Pharmaceutical, Corp. | Antibiotic composition |
| US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
| US6565882B2 (en) | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
| US6730320B2 (en) | 2000-02-24 | 2004-05-04 | Advancis Pharmaceutical Corp. | Tetracycline antibiotic product, use and formulation thereof |
| GEP20043285B (en) | 2000-03-30 | 2004-07-26 | Bristol Myers Squibb Co | Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections |
| US20040146554A1 (en) * | 2000-07-15 | 2004-07-29 | Sharma Virender K. | Method for the administration of acid-labile drugs |
| US20020064555A1 (en) * | 2000-09-29 | 2002-05-30 | Dan Cullen | Proton pump inhibitor formulation |
| US7105174B2 (en) * | 2000-10-13 | 2006-09-12 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-neoplastic product, use and formulation thereof |
| US7074417B2 (en) * | 2000-10-13 | 2006-07-11 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-viral product, use and formulation thereof |
| US7157095B2 (en) * | 2000-10-13 | 2007-01-02 | Advancis Pharmaceutical Corporation | Multiple-delayed release antifungal product, use and formulation thereof |
| US6541014B2 (en) | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
| US20020197314A1 (en) | 2001-02-23 | 2002-12-26 | Rudnic Edward M. | Anti-fungal composition |
| SE0101379D0 (sv) * | 2001-04-18 | 2001-04-18 | Diabact Ab | Komposition som hämmar utsöndring av magsyra |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| JP2006282677A (ja) * | 2001-10-17 | 2006-10-19 | Takeda Chem Ind Ltd | 酸に不安定な薬物の高含量顆粒 |
| JP4331930B2 (ja) * | 2001-10-17 | 2009-09-16 | 武田薬品工業株式会社 | 酸に不安定な薬物の高含量顆粒 |
| US8105626B2 (en) | 2001-10-17 | 2012-01-31 | Takeda Pharmaceutical Company Limited | Granules containing acid-unstable chemical in large amount |
| MXPA04007169A (es) * | 2002-01-25 | 2004-10-29 | Santarus Inc | Suministro transmucosal de inhibidores de bomba de protones. |
| US7125563B2 (en) * | 2002-04-12 | 2006-10-24 | Dava Pharmaceuticals, Inc. | Sustained release pharmaceutical preparations and methods for producing the same |
| US20030228363A1 (en) * | 2002-06-07 | 2003-12-11 | Patel Mahendra R. | Stabilized pharmaceutical compositons containing benzimidazole compounds |
| SE0203065D0 (sv) * | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
| MY148805A (en) * | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| US9107804B2 (en) * | 2002-12-10 | 2015-08-18 | Nortec Development Associates, Inc. | Method of preparing biologically active formulations |
| US20040114368A1 (en) * | 2002-12-13 | 2004-06-17 | Shyu Shing Jy | Light device having rotatable or movable view |
| EP1596838A2 (en) * | 2003-02-11 | 2005-11-23 | Torrent Pharmaceuticals Ltd | Once a day orally administered pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent |
| US20040185119A1 (en) * | 2003-02-26 | 2004-09-23 | Theuer Richard C. | Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency |
| BR8300543U (pt) * | 2003-04-09 | 2004-11-23 | Medley S A Ind Farmaceutica | Embalagem, ou kit de medicamentos, ou apresentação facilitadora da administração de medicamentos por parte dos pacientes |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| AU2004258949B2 (en) | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| CA2533292C (en) | 2003-07-21 | 2013-12-31 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
| AU2004258944B2 (en) | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| WO2005011637A1 (ja) * | 2003-08-04 | 2005-02-10 | Eisai Co., Ltd. | 用時分散型製剤 |
| JP2007502296A (ja) | 2003-08-11 | 2007-02-08 | アドバンシス ファーマスーティカル コーポレイション | ロバストペレット |
| US8062672B2 (en) | 2003-08-12 | 2011-11-22 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
| AU2004268641A1 (en) * | 2003-08-29 | 2005-03-10 | Dynogen Pharmaceuticals, Inc. | Compositions useful for treating gastrointestinal motility disorders |
| WO2005023184A2 (en) * | 2003-08-29 | 2005-03-17 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
| WO2005027877A1 (en) | 2003-09-15 | 2005-03-31 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
| TWI372066B (en) * | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
| US7608674B2 (en) * | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
| US7767768B2 (en) * | 2003-11-03 | 2010-08-03 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7335795B2 (en) | 2004-03-22 | 2008-02-26 | Ilypsa, Inc. | Crosslinked amine polymers |
| JP4740740B2 (ja) * | 2003-12-09 | 2011-08-03 | 大日本住友製薬株式会社 | 薬物含有粒子および該粒子を含む固形製剤 |
| RS20050796A (en) * | 2004-01-06 | 2007-08-03 | Panacea Biotec Ltd., | Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| WO2005123042A1 (en) * | 2004-06-10 | 2005-12-29 | Glatt Air Techniques, Inc. | Controlled release pharmaceutical formulation |
| WO2006014427A1 (en) | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
| KR101038403B1 (ko) * | 2004-07-28 | 2011-06-01 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 복수의 층을 갖는 필름-코팅된 정제 |
| AR051654A1 (es) * | 2004-11-04 | 2007-01-31 | Astrazeneca Ab | Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones |
| AR052225A1 (es) * | 2004-11-04 | 2007-03-07 | Astrazeneca Ab | Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones |
| WO2006066932A1 (en) * | 2004-12-24 | 2006-06-29 | Lek Pharmaceuticals D.D. | Stable pharmaceutical composition comprising an active substance in the form of solid solution |
| US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
| US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
| CN101405004A (zh) * | 2006-01-20 | 2009-04-08 | 大日本住友制药株式会社 | 新型薄膜衣片剂 |
| EP2012756A4 (en) * | 2006-04-20 | 2013-01-23 | Inventia Healthcare Private Ltd | MULTI-UNIT COMPOSITIONS |
| US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
| AU2007266574A1 (en) * | 2006-06-01 | 2007-12-06 | Dexcel Pharma Technologies Ltd. | Multiple unit pharmaceutical formulation |
| US8439033B2 (en) | 2007-10-09 | 2013-05-14 | Microdose Therapeutx, Inc. | Inhalation device |
| CA2736547C (en) * | 2008-09-09 | 2016-11-01 | Pozen Inc. | Method for delivering a pharmaceutical composition to patient in need thereof |
| JP2012518655A (ja) * | 2009-02-23 | 2012-08-16 | アプタリス ファーマテック インコーポレイテッド | プロトンポンプ阻害剤を含む制御放出組成物 |
| US8758779B2 (en) * | 2009-06-25 | 2014-06-24 | Wockhardt Ltd. | Pharmaceutical composition of duloxetine |
| AU2010263304A1 (en) | 2009-06-25 | 2012-02-02 | Astrazeneca Ab | Method for treating a patient at risk for developing an NSAID-associated ulcer |
| WO2011063150A2 (en) * | 2009-11-20 | 2011-05-26 | Handa Pharmaceuticals, Llc | Oral formulation for dexlansoprazole |
| CA2784041C (en) | 2010-01-05 | 2017-11-07 | Microdose Therapeutx, Inc. | Inhalation device and method |
| KR101143997B1 (ko) * | 2010-03-04 | 2012-05-09 | 한미사이언스 주식회사 | 유산균 제제 및 5-ｈｔ4 수용체 효능제를 함유하는 경구 투여용 복합 제제 및 이의 제조방법 |
| WO2011126327A2 (en) * | 2010-04-09 | 2011-10-13 | Hyundai Pharm Co., Ltd. | Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof |
| EP2563341A1 (en) * | 2010-04-26 | 2013-03-06 | Mahmut Bilgic | Pharmaceutical compositions inducing synergistic effect |
| BRPI1103093A2 (pt) * | 2011-06-03 | 2013-07-02 | Eurofarma Laboratarios Ltda | composiÇço farmacÊutica oral e uso da composiÇço farmacÊutica oral |
| MX2014007935A (es) | 2011-12-28 | 2014-11-14 | Pozen Inc | Composiciones y metodos mejorados para el suministro de omeprazol y de acido acetilsalicilico. |
| JP6273302B2 (ja) * | 2013-03-15 | 2018-01-31 | コリア ユナイテッド ファーマ． インコーポレーテッド | １日１回の投与で薬理学的臨床効果を提供するモサプリド徐放性製剤 |
| EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| CN108289849A (zh) * | 2015-06-26 | 2018-07-17 | 韩国联合制药株式会社 | 莫沙必利与雷贝拉唑的复合制剂 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| KR102034694B1 (ko) * | 2017-12-14 | 2019-10-22 | 한국유나이티드제약 주식회사 | 모사프리드와 라베프라졸을 함유하는 유핵정 복합제제 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5535031A (en) * | 1978-09-04 | 1980-03-11 | Shin Etsu Chem Co Ltd | Enteric coating composition |
| JPS5598120A (en) * | 1979-01-16 | 1980-07-25 | Shin Etsu Chem Co Ltd | Preparation of drug having enteric coating |
| FR2471186A1 (fr) * | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
| US4340582A (en) * | 1981-01-15 | 1982-07-20 | Abbott Laboratories | Erythromycin base tablets |
| US4377568A (en) * | 1981-08-12 | 1983-03-22 | Merck Sharp & Dohme (I.A.) Corp. | Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same |
| DK150008C (da) * | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
| JPS5973529A (ja) * | 1982-10-12 | 1984-04-25 | Sankyo Co Ltd | 被覆固形製剤の製造法 |
| US4525339A (en) * | 1982-10-15 | 1985-06-25 | Hoffmann-La Roche Inc. | Enteric coated oral dosage form |
| US4518433A (en) * | 1982-11-08 | 1985-05-21 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
| GB2132887A (en) * | 1982-11-15 | 1984-07-18 | Procter & Gamble | Enteric-coated anti-inflammatory compositions |
| US4556552A (en) * | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
| IE59287B1 (en) * | 1984-02-10 | 1994-02-09 | Benzon Pharma As | Diffusion coated multiple-units dosage form |
| US4568560A (en) * | 1984-03-16 | 1986-02-04 | Warner-Lambert Company | Encapsulated fragrances and flavors and process therefor |
| SE450087B (sv) * | 1985-10-11 | 1987-06-09 | Haessle Ab | Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial |
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| US5330982A (en) * | 1986-12-17 | 1994-07-19 | Glaxo Group Limited | Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith |
| SE8803822D0 (sv) * | 1988-10-26 | 1988-10-26 | Novel dosage form | |
| US5026559A (en) * | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
| NZ235877A (en) * | 1989-11-02 | 1992-09-25 | Mcneil Ppc Inc | Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence |
| JP3142919B2 (ja) * | 1991-11-06 | 2001-03-07 | 旭化成株式会社 | セルロース誘導体ラテックス及びその製法 |
| US5160742A (en) * | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
| SG42869A1 (en) * | 1992-08-05 | 1997-10-17 | Faulding F H & Co Ltd | Pelletised pharmaceutical composition |
| US5330759A (en) * | 1992-08-26 | 1994-07-19 | Sterling Winthrop Inc. | Enteric coated soft capsules and method of preparation thereof |
| CA2166730A1 (en) * | 1993-07-06 | 1995-01-19 | Robert T. Sims | H2 antagonist-gastrointestinal motility agent combinations |
| JP3017906B2 (ja) * | 1993-10-08 | 2000-03-13 | 信越化学工業株式会社 | 腸溶性コーティング剤分散液 |
| JP3710473B2 (ja) * | 1993-10-12 | 2005-10-26 | 三菱ウェルファーマ株式会社 | 腸溶性顆粒含有錠剤 |
| GB2285989A (en) * | 1994-01-28 | 1995-08-02 | Merck Frosst Canada Inc | Aqueous formulations for enteric coatings |
| EP0723436B1 (en) * | 1994-07-08 | 2001-09-26 | AstraZeneca AB | Multiple unit tableted dosage form i |
| SE9402431D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
| SE9600072D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients II |
-
1996
- 1996-01-08 SE SE9600072A patent/SE9600072D0/xx unknown
- 1996-12-20 US US08/750,936 patent/US6132771A/en not_active Expired - Lifetime
- 1996-12-20 WO PCT/SE1996/001736 patent/WO1997025065A1/en active IP Right Grant
- 1996-12-20 PT PT96944725T patent/PT814840E/pt unknown
- 1996-12-20 TR TR97/00917T patent/TR199700917T1/xx unknown
- 1996-12-20 KR KR1019970706235A patent/KR100486057B1/ko not_active IP Right Cessation
- 1996-12-20 PL PL96322176A patent/PL322176A1/xx unknown
- 1996-12-20 EE EE9700195A patent/EE9700195A/xx unknown
- 1996-12-20 HU HU9904094A patent/HUP9904094A3/hu unknown
- 1996-12-20 CN CNB96193607XA patent/CN1142792C/zh not_active Expired - Fee Related
- 1996-12-20 AU AU13240/97A patent/AU712572B2/en not_active Ceased
- 1996-12-20 SK SK1170-97A patent/SK117097A3/sk unknown
- 1996-12-20 DE DE69624910T patent/DE69624910T2/de not_active Expired - Fee Related
- 1996-12-20 JP JP9525130A patent/JPH11501949A/ja not_active Ceased
- 1996-12-20 IL IL12165296A patent/IL121652A/en not_active IP Right Cessation
- 1996-12-20 ES ES96944725T patent/ES2185816T3/es not_active Expired - Lifetime
- 1996-12-20 EP EP96944725A patent/EP0814840B1/en not_active Expired - Lifetime
- 1996-12-20 DK DK96944725T patent/DK0814840T3/da active
- 1996-12-20 AT AT96944725T patent/ATE228010T1/de not_active IP Right Cessation
- 1996-12-20 CZ CZ972808A patent/CZ280897A3/cs unknown
- 1996-12-20 BR BR9607344A patent/BR9607344A/pt not_active IP Right Cessation
- 1996-12-20 MX MX9706769A patent/MX9706769A/es not_active IP Right Cessation
- 1996-12-20 NZ NZ325976A patent/NZ325976A/xx unknown
- 1996-12-20 CA CA002214033A patent/CA2214033C/en not_active Expired - Fee Related
- 1996-12-26 AR ARP960105898A patent/AR008750A1/es not_active Application Discontinuation
- 1996-12-30 ZA ZA9610938A patent/ZA9610938B/xx unknown
-
1997
- 1997-01-08 ID IDP970026A patent/ID18383A/id unknown
- 1997-08-21 IS IS4550A patent/IS4550A/is unknown
- 1997-09-04 NO NO19974070A patent/NO316425B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO316425B1 (no) | Orale, farmasöytiske doseringsformer innbefattende en protonpumpeinhibitorog et prokinetisk middel, fremgangsmåte for fremstilling av slikedoseringsformer og anvendelse derav | |
| AU712669B2 (en) | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate | |
| EP0814839B1 (en) | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid | |
| JP3350054B2 (ja) | 複数単位の錠剤化された剤形▲ｉ▼ | |
| NO316865B1 (no) | Ny oral farmasoytisk doseringsform, fremgangsmate for dens fremstilling, og anvendelse derav | |
| EP1957081A1 (en) | Oral pharmaceutical dosage form comprising as active ingredients a proton pump inhibitor together with acetyl salicyclic acid | |
| MX2008006727A (en) | Oral pharmaceutical dosage form comprising as active ingredients a proton pump inhibitor together with acetyl salicyclic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |